Hemoptysis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 17: | Line 17: | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated.<ref name="ShigemuraWan2009">{{cite journal|last1=Shigemura|first1=Norihisa|last2=Wan|first2=Innes Y.|last3=Yu|first3=Simon C.H.|last4=Wong|first4=Randolph H.|last5=Hsin|first5=Michael K.Y.|last6=Thung|first6=Hoi K.|last7=Lee|first7=Tak-Wai|last8=Wan|first8=Song|last9=Underwood|first9=Malcolm J.|last10=Yim|first10=Anthony P.C.|title=Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience|journal=The Annals of Thoracic Surgery|volume=87|issue=3|year=2009|pages=849–853|issn=00034975|doi=10.1016/j.athoracsur.2008.11.010}}</ref><ref name="NoëJaffé2011">{{cite journal|last1=Noë|first1=G.D.|last2=Jaffé|first2=S.M.|last3=Molan|first3=M.P.|title=CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment|journal=Clinical Radiology|volume=66|issue=9|year=2011|pages=869–875|issn=00099260|doi=10.1016/j.crad.2011.03.001}}</ref> | *The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated.<ref name="ShigemuraWan2009">{{cite journal|last1=Shigemura|first1=Norihisa|last2=Wan|first2=Innes Y.|last3=Yu|first3=Simon C.H.|last4=Wong|first4=Randolph H.|last5=Hsin|first5=Michael K.Y.|last6=Thung|first6=Hoi K.|last7=Lee|first7=Tak-Wai|last8=Wan|first8=Song|last9=Underwood|first9=Malcolm J.|last10=Yim|first10=Anthony P.C.|title=Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience|journal=The Annals of Thoracic Surgery|volume=87|issue=3|year=2009|pages=849–853|issn=00034975|doi=10.1016/j.athoracsur.2008.11.010}}</ref><ref name="NoëJaffé2011">{{cite journal|last1=Noë|first1=G.D.|last2=Jaffé|first2=S.M.|last3=Molan|first3=M.P.|title=CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment|journal=Clinical Radiology|volume=66|issue=9|year=2011|pages=869–875|issn=00099260|doi=10.1016/j.crad.2011.03.001}}</ref> | ||
*During 2000-2005, in-hospital mortality rate of massive hemoptysis was 0%. | |||
*During 1995-1999, in-hospital mortality rate of massive hemoptysis was 15%. | |||
===Age=== | ===Age=== | ||
Revision as of 18:52, 15 February 2018
|
Hemoptysis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemoptysis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hemoptysis epidemiology and demographics |
|
Risk calculators and risk factors for Hemoptysis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- The mortality rate of patients with massive hemoptysis is approximately 50-100%, if left untreated.[1][2]
- During 2000-2005, in-hospital mortality rate of massive hemoptysis was 0%.
- During 1995-1999, in-hospital mortality rate of massive hemoptysis was 15%.
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Shigemura, Norihisa; Wan, Innes Y.; Yu, Simon C.H.; Wong, Randolph H.; Hsin, Michael K.Y.; Thung, Hoi K.; Lee, Tak-Wai; Wan, Song; Underwood, Malcolm J.; Yim, Anthony P.C. (2009). "Multidisciplinary Management of Life-Threatening Massive Hemoptysis: A 10-Year Experience". The Annals of Thoracic Surgery. 87 (3): 849–853. doi:10.1016/j.athoracsur.2008.11.010. ISSN 0003-4975.
- ↑ Noë, G.D.; Jaffé, S.M.; Molan, M.P. (2011). "CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment". Clinical Radiology. 66 (9): 869–875. doi:10.1016/j.crad.2011.03.001. ISSN 0009-9260.